Canakinumab is an anti-IL-1β monoclonal antibody currently approved for several rare rheumatological conditions (including cryopyrin-associated periodic syndromes, refractory gout, and Muckle–Wellis syndrome), where increased inflammasome activity and production of IL-1β are thought to drive disease activity [11]. The gene discussed is IL1B; the disease is gout.